ABLYNX ANNOUNCES WEBCAST OF ITS PRESENTATION AT THE 5th ANNUAL PIPER JAFFRAY EUROPE HEALTHCARE CONFERENCE
(Thomson Reuters ONE) -
GHENT, Belgium, 15 June 2010 - Ablynx [Euronext Brussels: ABLX] today announced
that it will webcast its corporate presentation at the 5th Annual Piper Jaffray
Europe Healthcare Conference on Tuesday, 22 June 2010 at 02.30 pm BST / 03.30
p.m. CET.
The presentation, followed by a Q&A, will be hosted by Dr Edwin Moses, CEO and
Chairman of Ablynx. The presentation will be webcast live and may be accessed on
the home page of Ablynx's website at www.ablynx.com
replay of the webcast will also be available on the Company's website for 30
days, by default.
To ensure a timely connection, it is recommended that users register at least
10 minutes prior to the scheduled webcast.
-ends-
About Ablynx [Euronext Brussels: ABLX] - http://www.ablynx.com
Founded in 2001 in Ghent, Belgium, Ablynx is a biopharmaceutical company focused
on the discovery and development of Nanobodies, a novel class of therapeutic
proteins based on single-domain antibody fragments, for a range of serious and
life-threatening human diseases. The Company currently has over 230 employees.
Ablynx completed a successful IPO on Euronext Brussels [ABLX] on 7 November
2007 and raised ?50 million through an SPO in March 2010.
Ablynx is developing a portfolio of Nanobody-based therapeutics in a number of
major disease areas, including inflammation, thrombosis, oncology and
Alzheimer's disease. Ablynx now has over 25 programmes in its therapeutic
pipeline including four Nanobodies in clinical development. So far, Nanobodies
have been successfully generated against more than 190 different protein targets
including several complex targets such as chemokines, GPCRs, ion channels and
viruses, which are typically very difficult to address with conventional
monoclonal antibodies. Efficacy data have been obtained in 28 in vivo models for
Nanobodies against a range of different targets.
Ablynx has an extensive patent position in the field of Nanobodies for
healthcare applications. It has exclusive and worldwide rights to more than 130
families of granted patents and pending patent applications, including the
Hamers patents covering the basic structure, composition, preparation and uses
of Nanobodies.
For more information, please contact
Ablynx:
Dr. Edwin Moses
Chairman and CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 / +32 (0)473 39 50 68
e: edwin.moses(at)ablynx.com
Eva-Lotta Allan
Chief Business Officer
t: +32 (0)9 262 00 75
m: +32 (0)475 78 36 21 / +44 (0)7990 570 900
e: eva-lotta.allan(at)ablynx.com
[HUG#1424191]
Complete version of the press release: http://hugin.info/137912/R/1424191/372852.pdf
Unternehmensinformation / Kurzprofil:
Datum: 15.06.2010 - 18:15 Uhr
Sprache: Deutsch
News-ID 22488
Anzahl Zeichen: 0
contact information:
Town:
Ghent
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 269 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"ABLYNX ANNOUNCES WEBCAST OF ITS PRESENTATION AT THE 5th ANNUAL PIPER JAFFRAY EUROPE HEALTHCARE CONFERENCE"
steht unter der journalistisch-redaktionellen Verantwortung von
Ablynx (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
